Q1 Earnings Forecast for VRDN Issued By B. Riley

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Viridian Therapeutics in a research note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel expects that the company will post earnings of ($1.09) per share for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. B. Riley also issued estimates for Viridian Therapeutics’ Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.30) EPS, FY2025 earnings at ($4.74) EPS, FY2026 earnings at ($4.95) EPS, FY2027 earnings at ($3.61) EPS and FY2028 earnings at ($2.64) EPS.

VRDN has been the subject of several other research reports. Wells Fargo & Company restated an “equal weight” rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. TD Cowen began coverage on Viridian Therapeutics in a research report on Monday, November 25th. They set a “buy” rating on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Royal Bank of Canada lifted their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

Viridian Therapeutics Trading Up 3.9 %

NASDAQ VRDN opened at $15.88 on Wednesday. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -3.68 and a beta of 1.05. Viridian Therapeutics has a 52 week low of $11.40 and a 52 week high of $27.20. The business has a 50 day moving average price of $17.86 and a 200-day moving average price of $19.64. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.24. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of VRDN. FMR LLC boosted its position in Viridian Therapeutics by 16.8% in the third quarter. FMR LLC now owns 11,183,478 shares of the company’s stock worth $254,424,000 after purchasing an additional 1,610,130 shares during the last quarter. Loomis Sayles & Co. L P purchased a new position in Viridian Therapeutics in the fourth quarter worth $26,845,000. Price T Rowe Associates Inc. MD raised its stake in shares of Viridian Therapeutics by 2,847.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company’s stock valued at $25,436,000 after buying an additional 1,281,799 shares during the period. Deep Track Capital LP raised its stake in shares of Viridian Therapeutics by 20.6% in the fourth quarter. Deep Track Capital LP now owns 4,522,741 shares of the company’s stock valued at $86,701,000 after buying an additional 771,796 shares during the period. Finally, Parkman Healthcare Partners LLC raised its stake in shares of Viridian Therapeutics by 155.9% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company’s stock valued at $20,850,000 after buying an additional 662,634 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.